
Recommendations on adoptive cell therapy with tumor-infiltrating lymphocytes that address the newly approved therapy lifileucel explore safe administration practices and optimal patient selection based on individual characteristics.

Your AI-Trained Oncology Knowledge Connection!


Recommendations on adoptive cell therapy with tumor-infiltrating lymphocytes that address the newly approved therapy lifileucel explore safe administration practices and optimal patient selection based on individual characteristics.

In a prognostic study, an artificial intelligence model significantly outperformed oncologists in predicting short-term mortality, resulting in a 60% positive predictive value vs 34.8%, which involved 57 physicians and 17 advanced practice clinicians.

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

The standard first-line treatment for patients with HER2-positive metastatic breast cancer is pertuzumab and trastuzumab, which are anti-HER2 antibodies, plus a taxane.

A deep and durable response rate was seen with linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

Patients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.

More than half of all patients do not remember their physicians’ recommendations and treatments unless prompted.

A cyberattack on Change Healthcare disrupted patient scheduling, billing, and potentially exposed patient data. It caused financial strain on medical practices and took weeks to recover from.
